PDGFRB and schwannoma: These are promising results, but examine PDGFR-β in isolation; as patient-derived schwannomas express and activate both PDGFR isoforms, the paradoxical decreased effect observed at higher nilotinib concentration could be due to increased activation of alternative receptors, such as PDGFR-α.